Yasuhiro Terazaki
Kurume University · 43 works · 526 citations · h-index 13
Top works
- Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapy
- Focal Cholesterol Granuloma in the Anterior Mediastinum: [18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography and Magnetic Resonance Imaging Findings
- Long-term survivors with pN2 non-small cell lung cancer after a complete resection with a systematic mediastinal node dissection
- DIRECT INFLUENCES OF PRO-INFLAMMATORY CYTOKINES (IL-1β, TNF-α, IL-6) ON THE PROLIFERATION AND CELL-SURFACE ANTIGEN EXPRESSION OF CANCER CELLS
- PD ‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer
- Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis
- Nuclear Y-Box Binding Protein-1, a Predictive Marker of Prognosis, Is Correlated with Expression of HER2/ErbB2 and HER3/ErbB3 in Non-small Cell Lung Cancer
- An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
- Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: Novel concepts for successful cytokine gene therapy
- Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma
- Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer
- Expired Gas Analysis During Exercise Testing Pre-pneumonectomy
- Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens
- Right-sided diaphragmatic rupture due to blunt trauma: report of four cases
- Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer
- Treatment Results of Non-small Cell Lung Cancer in Octogenerians.
- Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)—IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201
- Intraoperative marking of an impalpable pulmonary nodule using the Hybrid OR System
- Personalized Peptide Vaccination for Refractory Small Cell Lung Cancer
- Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination